S&P Futures
5,953.75 +15.00 (+0.25%) Dow Futures
43,530.00 +130.00 (+0.30%) Nasdaq Futures
20,818.25 +50.50 (+0.24%) Russell 2000 Futures
2,339.90 +5.80 (+0.25%) Crude Oil
69.72 +0.33 (+0.48%) Gold
2,625.30 -5.70 (-0.22%)
Pulmonx Corporation (LUNG)
After hours:
| Previous Close | 6.12 |
| Open | 6.05 |
| Bid | 4.36 x 200 |
| Ask | 7.60 x 200 |
| Day's Range | 5.84 - 6.15 |
| 52 Week Range | 5.46 - 14.84 |
| Volume | |
| Avg. Volume | 242,312 |
| Market Cap | 236.927M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | Feb 19, 2025 - Feb 24, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
Business WirePulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers
REDWOOD CITY, Calif., November 19, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and emphysema.
GlobeNewswirePulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic ob
